Researchers have discovered a previously unknown pathway that could explain why androgens remain and prostate cancer progresses despite treatment with androgen deprivation therapy.
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, including those that typically escape detection, with fewer toxic side effects.
Researchers at UT Southwestern Medical Center have identified a protein that causes human cell membranes to break open in a form of inflammatory programmed cell death called necroptosis.
FDA published a perspective article in JAMA that describes the agency’s current regulatory thinking for the development of CAR T-cell therapies.
FDA approved Augmentin XR (amoxicillin-clavulanate potassium) under the Commissioner’s National Priority Voucher pilot program, marking the first approval achieved through this review pathway.
FDA granted Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) Breakthrough Therapy designation as second line for patients with relapsed/refractory multiple myeloma.
FDA has cleared the Hugo robotic-assisted surgery system for use in urologic surgical procedures.
FDA approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first CAR T-cell therapy in the U.S. for treatment of adults with marginal zone lymphoma who have failed treatment with or relapsed after two or more prior lines of therapy.
Stepping into the NCI director’s job at the end of a nerve-racking year, Anthony Letai wants you to know that the federal government is not going out of the business of cancer research.
Anthony G. Letai’s initiation as the 18th director of the National Cancer Institute wasn’t exactly smooth.
